Gosset Ownership
Private
Employees
~10
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Fekra Therapeutics General Information
Fekra Therapeutics develops novel first-in-class small molecule therapeutics using its proprietary Curiositome platform. Its lead candidate, FT‑01, targets BMX kinase for castration-resistant prostate cancer and has advanced to the clinical stage. The pipeline includes additional programs targeting solid tumors, non-solid tumors, and inflammatory diseases. The company leverages structure-based drug design and AI-driven discovery approaches to address unmet needs in oncology and immunology.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Boston, Massachusetts
United States
United States
Drug Pipeline
No pipeline data available
Key Partnerships
Fekra Therapeutics Funding
No funding data available
To view Fekra Therapeutics's complete valuation and funding history, request access »